$0.01
(0.13%)
Add to watchlist
Create an alert
Stocks and Shares ISARelay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Company Information
About this company
Key people
Sanjiv K. Patel
President, Chief Executive Officer, Director
Thomas Catinazzo
Chief Financial Officer
Donald A. Bergstrom
President - Research and Development
Peter Rahmer
Chief Corporate Development Officer
Brian R. Adams
Chief Legal Officer, Secretary
Alexis A. Borisy
Independent Chairman of the Board
Lonnel Coats
Independent Director
Habib Joseph Dable
Independent Director
Linda A. Hill
Independent Director
Douglas S. Ingram
Independent Director
Click to see more
Key facts
- Shares in issue173.32m
- EPICRLAY
- ISINUS75943R1023
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.42bn
- Employees188
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.